Day One, Tuesday 30th March 2010
09:00 Registration and refreshments
09:30 Opening address from the co-chairs
Stephen Minger
Senior Lecturer in Stem Cell Biology
King’s College London
Ruth McKernan
Chief Scientific Officer
Pfizer Regenerative Medicine*
09:40 Prospects for the global regenerative medicine market
• Dynamics of the regenerative medicine market
• Why academic collaborations are increasingly important
• What does industry want?
Alain Vertes
Global Alliance Director
Roche*
10:20 Mapping regulations for regenerative medicine in the UK
• Regulations for regenerative medicine
• The regulatory landscape in the UK
• How to make a regulatory route map
John Connolly
Head of Cell & Gene Therapies
Department of Health
11:00 Morning refreshments
11:20 Bioprocessing of regenerative medicines
• Routes to faster production methods
• Standardisation
• Ensuring cGMP
12:00 Scaling-up in the lab with hESCs
• Purifying and maintaining stem cells under cGMP conditions
• Evidence for reliable production and quality control of product manufacturing
• Rigorous safety testing in preclinical models
Jane Lebkowski
Chief Scientific Officer
Geron
12:40 Networking lunch
14:00 Automation- the route to successful scale-up and manufacture for cell-based therapies?
• Different manufacturing approaches using standard cell culture vessels
• Developing cost-effective methods for scaling up in manufacture
• Automating production of cells and tissues for clinical trials
Rosemary Drake
Chief Scientific Officer
The Automation Partnership
14:40 The immune response to stem cell-derived tissues
• Direct and indirect pathways of MHC allorecognition
• Distinction between antigenicity and immunogenicity
• Possible approaches to promote immune tolerance to allogeneic tissues
Robert Lechler
Vice Principal
King’s College London
15:20 Afternoon refreshments
15:40 Regenerative medicine clinical trials- challenges associated with translation into man
• Preliminary box-ticking
• Clinical trial registration
• When things go wrong: ensuring the cash keeps flowing
Anthony Mathur
Consultant Cardiologist
Barts and the London Hospital
16:20 Successful bone marrow gene therapy for SCID
Robert Gaspar
Professor of Paediatrics and Immunology
Great Ormond Street Hospital
17:00 Round table discussions. Choose from:
Is there such a thing as personalised medicine in cell therapy?
Panellists: Stephen Minger, Senior Lecturer in Stem Cell Biology, King’s College London
Rosemary Drake, Chief Scientific Officer, The Automation Partnership
Julie Daniels, Director, Cells for Sight Tissue Bank , Moorfields Eye Hospital
David Newble, Chief Executive Officer, The Automation Partnership*
OR
Engaging with the global regenerative medicine market
Topics will include: obtaining venture capital, engaging with partners in industry & acadaemia, and investment opportunities in the post credit crunch era. Commercialising your product, and keeping abreast of regulatory requirements will also be discussed. If you would like to submit a question to the panel, please email: john.shah@visiongainglobal.com.
Panellists: Brian Meltzer, Senior Director, Venture Program Management, Johnson & Johnson Corporate Development*
Robert Pinnock, Director, Scientific & Academic Liaison, Merck Sharp & Dohme
Alan Lamont, Director of Science and Technology Alliances, AstraZeneca
Jan Lundberg, Executive Vice President, Discovery Research, AstraZeneca
Iphigenie Charatsi, Business Manager, UK Stem Cell Bank*
17:40 Closing remarks from the chair
17:50 Networking drinks
